Advancing quality use of medicines in NSW

Fortnightly TAG Mail - resources list 26th September 2024

NSW TAG ACTIVITIES

2024 Meetings NSW TAG General Meetings - 31st October 2.30-4pm

NSW TAG Annual General Meeting

- 31st October 4- 4.30pm

Open email discussions- nil

Recently completed email discussions and surveys

- Local written procedures outlining documentation requirements for handling of ADRs incl reporting to DTCs
- Protocols for critical medicines in NSW public facilities
- Ongoing infliximab for immune therapy colitis
- Handling of medicines by perfusionists

Contact Sasha Bennett at <u>sasha.bennett@svha.org.au</u> for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

BJCP: Errors associated with co-names of medicines - link

BJCP: Efficacy and safety of antidepressants for pain in older adults- link

BJCP: The effect of down-titration and discontinuation of heart failure pharmacotherapy in older people: A systematic review and meta-analysis - link

BMJ: Protecting early career physicians from commercial influence - link

BMJ Open: Cost comparison analysis of continuous versus intermittent antimicrobial therapy infusions in inpatient and outpatient care: real-world data from Finland - Link

BMJ Quality & Safety: Editorial- Measuring gist-based perceptions of medication benefit-to-harm ratios - link

IJQHC: Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill - link

JAMA: JAMA Clinical Guidelines Synopsis: Evaluation of Suspected Antibiotic Allergies - <u>link</u> JAMA IM: - Patient-Directed Education to Promote Deprescribing- <u>link</u>

JAMA Psychiatry: - Patient Self-Guided Interventions to Reduce Sedative Use and Improve Sleep: The YAWNS NB Randomized Clinical Trial - link

MJA: Summary of the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome: an Australian perspective - link

MJA: Updating the diagnosis and management of iron deficiency in the era of routine ferritin testing of blood donors by Australian Red Cross Lifeblood - link

NIHR: - Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model - link

Pediatrics: Special Requirements of Electronic Health Record Systems in Pediatrics- link

Pharmacotherapy: Delirium event and associated treatment modifications among older adults with Alzheimer's disease: An interrupted time-series analysis of Medicare data - link

OTHER NEWS

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- New milestones achieved in medication safety link
- Have your say on the draft Medication Management at Transitions of Care Stewardship Framework link
- Launch of Australia's first care standard for COPD link

NSW Health

- Mental Health Outcomes and Assessment Tools (MHOAT) Collection and Reporting Requirements (PD2024 031) [24 September 2024]
- Responding to the health care needs of people with disability (PD2024 030) [19 September 2024]
- Finalists announced for the NSW Health Awards 2024 [23 September 2024]

- Public health warning: Heroin overdoses after using drugs thought to be cocaine [13 September 2024]
- Community urged to get vaccinated as whooping cough notifications continue to rise [12 September 2024]

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found here

- Improving access to menopause care in NSW link
- Flexible diuretic action plan for heart failure link

AHHA

- Australian Collaborative Commissioning program supporting frail and elderly recognised internationally - link

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Patient-Reported Outcome Measure Recommendations for Low Back Pain - link

AHPRA

- Meeting your professional obligations when using Artificial Intelligence in healthcare - link

Australian Government Department of Health

- Palliative care education and training for the aged care workforce - Communication toolkit

Australian Institute for Health and Welfare (AIHW)

- Suicide and self-harm monitoring: Suicide registers update; Dementia in Australia update
- Pharmaceutical Benefits Scheme prescriptions over time monthly data

PBS

- PBS arrangements due to shortage of tenofovir with emtricitabine tablets - 23 September 2024 - link

TGA

- Database of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs:
- -- Amvuttra (vutrisiran) for hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy
- -- <u>COMIRNATY</u> Original/Omicron BA.4-5 Vaccine has been provisionally approved for immunisation against coronavirus disease 2019 (COVID-19) in individuals 6 months of age or older
- -- Lokelma (sodium zirconium cyclosilicate hydrate) for hyperkalaemia in adult patients
- -- Kyprolis (carfilzomib) approved to treat relapsed or refractory multiple myeloma
- -- <u>Mounjaro</u> (tirzepatide) as an adjunct to a reduced-calorie diet and increased physical activity, for chronic weight management
- -- Opdivo (nivolumab), in combination with platinum-doublet chemotherapy, for the neoadjuvant treatment of patients with resectable non-small cell lung cancer
- -- <u>Velsipity</u> (Etrasimod) approved for adults with moderately to severely active ulcerative colitis who have not benefited from prior therapies
- Australian prescription medicine decision summaries:
- -- Zilbrysq (zilucoplan) approved as an add-on to standard therapy for generalised myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive

REPORTS AND PUBLICATIONS – INTERNATIONAL

All Wales Medicines Strategy Group

- Infliximab can be made available within NHS Wales for the treatment of immune checkpoint inhibitor (ICI)-induced enterocolitis $-\frac{link}{link}$
- Vedolizumab can be made available within NHS Wales for the treatment of immune checkpoint inhibitor (ICI)-induced enterocolitis <u>link</u>

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

Agency for Healthcare Research and Quality (AHRQ) USA

- Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain - link

British National Formulary

- BNF/BNFC newsletter: September 2024 including:
- -- Cabergoline: updated important safety information
- -- Hyperkalaemia: updated guidance on management
- -- Salbutamol: new indication and dose for moderate to severe hyperkalaemia.
- -- Topiramate (Topamax®): introduction of new safety measures, including a Pregnancy Prevention Programme [MHRA/CHM advice]
- -- Warfarin: be alert to the risk of drug interactions with tramadol [MHRA/CHM advice] (advice in warfarin sodium and acenocoumarol)

Canadian Agency for Drugs and Technologies in Health

- Cost-Effectiveness of Conjugate Pneumococcal Vaccines in At-Risk Adults Aged 18 to 64 Years link
- Review of Guidelines on Second-Line Therapy for Patients With Relapsing-Remitting Multiple Sclerosis: A 2024 Update <u>link</u>
- Thrombopoietin Receptor Agonists as Second-Line Treatment in Children With Ongoing Immune Thrombocytopenia <u>link</u>
- Methoxyflurane Inhalation as an Analgesic for Minor Gynecological, Ambulatory, or Emergency Procedures link

electronic Medicines Compendium (eMC) (UK)

- New products
- -- Agamree (vamorolone) for Duchenne muscular dystrophy in patients aged 4 years and older
- -- Influenza vaccine Tetra MYL for prophylaxis of influenza in adults and children from 6 months of age, especially those who run an increased risk of associated complications. Its use should be based on official recommendations
- -- Obgemsa (Vibegron) 75 mg tablets for adult patients with overactive bladder syndrome
- -- Pedmarqsi (sodium thiosulfate) 80 mg/mL infusion for prevention of ototoxicity induced by cisplatin in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours
- Updated SPCs
- -- Dupixent (dupilumab) 200 mg pre-filled pen is for use in adult and paediatric patients aged 2 years and older, pre-filled syringe is for use in adult and paediatric patients aged 6 months and older. In children aged 6 months to ≤12 years, it should be given by a caregiver. All formulations now cover treatment of eosinophilic esophagitis and COPD
- -- Tagrisso (osimertinib) for use in combination with pemetrexed and platinum based chemotherapy as 1st-line treatment of adults with locally advanced or metastatic non-small cell lung cancer with activating EGFR mutations, based on final results of FLAURA2 study

European Medicines Agency (EMA)

- European Medicines Agency recommends extending indication of Imvanex® mpox and smallpox vaccine to include adolescents <u>link</u>
- European CHMP recommends the granting of marketing authorisations for:
- -- aflibercept biosimilar (<u>Afglir</u>) (<u>Opuviz</u>) for wet AMD, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema & visual impairment due to myopic choroidal neovascularisation
- -- Elahere ($\underline{\text{mirvetuximab soravtansine}}$) for adults with folate receptor-alpha (FR α) positive epithelial ovarian, fallopian tube and primary peritoneal cancer
- -- Hetronifly (<u>serplulimab</u>) in combination with carboplatin and etoposide for first-line treatment of adults with extensive-stage small cell lung cancer

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

- -- Hympavzi (<u>marsracimab</u>) for prophylaxis of bleeding episodes in patients with severe haemophilia A or B ≥12yrs, weighing ≥35 kg, with severe haemophilia A without factor VIII inhibitors or severe haemophilia B without factor IX inhibitors
- -- <u>Penbray</u> (Meningococcal group A, B, C, W and Y vaccine) for active immunisation of individuals 10 years of age and older to prevent invasive disease caused by Neisseria meningitidis groups A, B, C, W, and Y. The use of this vaccine should be in accordance with official recommendations
- -- generic pomalidomide (<u>Teva</u>) in combination with bortezomib and dexamethasone for multiple myeloma in adults who have received at least one prior treatment regimen including lenalidomide
- -- <u>Theralugand</u> (lutetium [177Lu] chloride) for the radiolabelling of carrier molecules that have been specifically developed/authorised for radiolabelling with lutetium (177Lu) chloride. Not for direct use.
- European CHMP recommends a change to the marketing authorisation for:
- -- <u>Aflunov</u> (zoonotic influenza vaccine [H5N1] (surface antigen, inactivated, adjuvanted) to include vaccination of children from the age of 6 months for active immunisation against H5N1 subtype of Influenza A virus
- -- benralizumab (<u>Fasenra</u>) to include use as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis
- -- <u>Buccolam</u> (midazolam) to include treatment of prolonged, acute, convulsive seizures in infants from 3 months to adults
- -- dupilumab (<u>Dupixent</u>) to include treatment of eosinophilic esophagitis in adults and children aged ≥1 year, weighing ≥15 kg who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy
- -- pembrolizumab (<u>Keytruda</u>) to include use in combination with chemoradiotherapy for treatment of FIGO 2014 Stage III-IVA locally advanced cervical cancer in adults, who haven't received prior definitive therapy
- -- <u>Pravafenix</u> (fenofibrate/pravastatin) to include use for treatment of mixed hyperlipidaemia in adults at high CV risk when LDL-C levels are adequately controlled on treatment with moderate-intensity statin regimen
- -- <u>Synjardy</u> (empagliflozin/metformin) to include use in children aged 10 years and above for type 2 diabetes mellitus as an adjunct to diet and exercise
- -- turoctocog alfa pegol (<u>Esperoct</u>) for treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency), to include use in all age groups (currently limited to use in those aged 12 years and above)
- -- Zaficefta (ceftazidime/avibactam) to include treatment of infants from birth for complicated intraabdominal infection, complicated urinary tract infection, including pyelonephritis & hospital-acquired pneumonia including ventilator associated pneumonia
- European CHMP recommends adoption of new indication for:
- -- apremilast (<u>Otezla</u>) for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years and weighing at least 20 kg who are candidates for systemic therapy
- -- daratumumab (<u>Darzalex</u>) in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
- -- pembrolizumab (<u>Keytruda</u>) in combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy
- European CHMP recommends refusal of authorisation for pegcetacoplan (<u>Syfovre</u>) for the treatment of geographic atrophy caused by age-related macular degeneration (AMD)
- Companies withdraw applications for:
- -- marketing authorisation of bimatoprost (<u>Durysta</u>) for the reduction of intraocular pressure in adults with open angle glaucoma or ocular hypertension
- -- use of <u>Sialanar</u> (glycopyrronium bromide) in the treatment of severe drooling in children aged 2 to 3 years old

An initiative of NSW clinical pharmacologists & pharmacists

-- extending use of atezolizumab (Tecentriq) to include treatment of adults with hepatocellular carcinoma whose cancer has been removed by surgery or other techniques and is at high risk of coming back

European Respiratory Society

- Results of ELVIS-Kids trial show hypertonic saline nasal drops can reduce the duration of the common cold in young children - <u>link</u>

Food and Drug Administration (FDA) USA

- New Drug approvals
- -- Agneursa (levacetylleucine) and Miplyffa (arimoclomol) for Niemann-Pick Disease Type C
- <u>amivantamab-vmjw</u> with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations
- -- atezolizumab and hyaluronidase-tqjs for subcutaneous injection link
- -- Benralizumab for EGPA Vasculitis Indication
- -- <u>Bimekizumab</u> for Three Rheumatologic Conditions, the first and only dual IL-17A and IL-17F inhibitor approved to treat four chronic immune-mediated inflammatory diseases
- -- Cobenfy (xanomeline and trospium chloride) drug with new mechanism of action for schizophrenia
- -- Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis
- -- FluMist Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration
- -- Isatuximab First-Line for Transplant-Ineligible MM
- -- Subcutaneous Ocrelizumab for relapsing MS
- -- <u>osimertinib</u> for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy
- -- Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack for early high-risk breast cancer
- -- <u>pembrolizumab</u> with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
- -- Adjuvant Ribociclib in Earlier Stage Breast Cancer

Medicines and Healthcare products Regulatory Agency (MHRA)

- Launches new strategy for improving safety communications on World Patient Safety Day: Improving information to patients and healthcare professionals link
- Fruquintinib approved to treat adults with metastatic colorectal cancer link
- Dupilumab approved for adults with uncontrolled COPD and raised eosinophils link

Monthly Index of Medical Specialities (MIMS) UK

- Benilexa (levonorgestrel) IUD approved for longer contraceptive use link
- MIMS summary: Trokide, a new tiotropium inhaler for patients with COPD link
- Obesity treatments compared in new MIMS resource link

NHS England

- Healthier You NHS Diabetes Prevention Programme Gestational Diabetes Mellitus (GDM) leaflet
- Patient Group Direction (PGD) for the administration of COVID-19 vaccines to individuals aged 5 years and over link
- Service specification: hepato-pancreatic biliary (HPB) pancreatic and periampullary cancers link
- Service specification: hepato-pancreatic biliary (HPB) primary liver, secondary liver, perihilar biliary tract and gallbladder cancers link
- Service specification: specialist gynaecological cancer link
- ACT NOW Sickle Cell Acronym link
- National Dose Banding Table Teclistamab 10mg/mL Teclistamab 90mgmL
- National patient safety alert: Risk of oxytocin overdose during labour and childbirth link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

National Institute for Health and Care Excellence (NICE) UK

- Implementing an antimicrobial prescribing strategy for ear infection in children link
- Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (<u>TA1007</u>)
- Trifluridine—tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)
- NICE-recommended digital therapies for depression and anxiety could free up thousands of NHS therapist hours link
- Burosumab for treating X-linked hypophosphataemia in children and young people, upated (HTS8)

National Institute for Health and Care Research (NIHR)

- NIHR Commentaries: How can we support the mental health of children with epilepsy? link
- Clinical and cost-effectiveness of clopidogrel resistance genotype testing after ischaemic stroke or transient ischaemic attack: a systematic review and economic model link
- Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT link
- NIHR commentaries: Chronic migraine: which drugs are best? link
- NIHR Commentaries: Dialysis for kidney failure: evidence to improve care link
- NIHR Commentaries: Is long COVID linked with orthostatic intolerance? link

Office of Health Economics, UK

- Report: The Cost of Drug Shortages - link

Reform, UK

- Prescription for Prevention: A new model of primary care - link

Royal Pharmaceutical Society

- Launches two new Advanced Pharmacist curricula, mental health and critical care - link

Specialist Pharmacy Services NHS UK

- Understanding the characteristics of Comirnaty 10 (JN.1) ready to use vaccine link
- Understanding the characteristics of Comirnaty 3 (THREE) (JN.1) concentrate vaccine link
- Understanding the characteristics of Comirnaty 30 (JN.1) vaccine link
- Understanding the characteristics of Spikevax (JN.1) vaccine link
- Using generic liposomal amphotericin B link

UK Health Security Agency

- Green Book updated for Covid-19, smallpox and mpox
- Antimicrobial resistance awareness: toolkit for healthcare providers link
- Collection: Public health in prisons and secure settings link

World Health Organisation (WHO)

- Guidance for best practices for clinical trials link
- WHO recommendation on screening of pregnant women for intrapartum antibiotic prophylaxis for the prevention of early onset group B streptococcus disease in newborns <u>link</u>
- World leaders commit to decisive action on antimicrobial resistance link

MEDICATION SAFETY

Electronic Medicines Compendium (eMC)

- Revised SPCs
- -- Adcetris (brentuximab) updates to the already approved Hodgkin lymphoma indication, to include patients with stage III disease
- -- Dexamethasone hiccups added as potential ADR with frequency unknown

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

- -- Dostinex (cabergoline) Tablets should not be used in women with pregnancy-induced hypertension, for example, post-partum hypertension, unless the potential benefit is judged to outweigh the possible risk, except for toxaemia of pregnancy
- -- Dynastat (parecoxib) updated with European PRAC recommendation regarding the systemic use of NSAID-containing products during pregnancy
- -- Epilim (sodium valproate) products potential increased risk of neurodevelopmental disorders in children born to men treated with valproate in the 3 months prior to conception. Male patients & their female partners should use effective contraception during and for ≥3 months after stopping treatment -- Equasym XL (methylphenidate hydrochloride) 'logorrhoea' (incoherent talkativeness) as an ADR of unknown frequency.
- -- FEIBA (factor VIII inhibitor bypassing activity) increases Fibrin D-dimer with unknown frequency
- -- Gardasil 9 (human papillomavirus 9-valent vaccine) 'Injection site nodule' as a possible ADR
- -- Gaviscon Advance (sodium alginate, potassium bicarbonate) including Aniseed flavour Oral Suspension and Mint Chewable Tablets diarrhoea, nausea, & vomiting added as uncommon ADRs -- Isovorin Solution (calcium levofolinate) several changes including: information about interactions between levofolinic acid and chloramphenicol, and levofolinic acid and fluorouracil
- -- Leflunomide may impair wound healing after surgery. Prescribers are advised to consider pausing treatment in the peri-surgical period based on an individual risk benefit assessment
- -- MenQuadfi (meningococcal Group A, C, W135 and Y conjugate vaccine) anaphylaxis (very rare) and hypersensitivity (frequency unknown) added as potential ADRs
- -- Metoject PEN (methotrexate) information on photosensitivity reactions & interaction with metamizole updated, following a European periodic safety update report single assessment
- -- Mounjaro (tirzepatide) KwikPen dysgeusia (taste disorder) as an uncommon ADR
- -- Octagam 5% and Panzyga (human normal immunoglobulin) now for use in measles pre-/post exposure prophylaxis for susceptible adults, children and adolescents (0-18 years) in whom active immunisation is contraindicated or not advised
- -- Retsevmo (selpercatinib) epiphysiolysis of femoral head reported in ≤ 6.4% of paediatric patients
- -- Revestive (teduglutide) use in children aged 4 months corrected gestational age and above
- -- Scopoderm (hyoscine) 1.5mg Patch risk of anticholinergic side effects, including hyperthermia
- -- Tecentriq (atezolizumab) IV formulation is not intended for SC administration and should be administered via IV infusion only (not IV push/bolus). It stresses importance of checking product labels to ensure correct formulation (IV or SC) is being administered to the patient, as prescribed
- -- Tioguanine, in combination with other immunosuppressive or chemotherapeutic agents, increases risk of severe or atypical viral, fungal or bacterial infections
- -- Tranexamic acid (Tillomed) in cases of haematuria of renal origin, especially in haemophilia, there is a risk of urinary obstruction which if left untreated can lead to renal insufficiency, UTI, hydronephrosis and anuria
- -- Veklury (remdesivir) pharmacodynamic properties changed due to availability of new preclinical data on the antiviral activity of remdesivir against the Omicron subvariants XBF, XBB.1.16, FL.22, XBB.2.3.2, EG.5.1, EG.1.2, BA.2.86 and XBB.1.9.2
- -- Yescarta (axicabtagene ciloleucel) secondary malignancies (T-cell malignancies) following treatment of haematological malignancies with BCMA- or CD19-directed CART-cell therapy. In this event the company is to be contacted to obtain instructions on patient samples to collect for testing Risk minimisation materials
- -- Biogen Healthcare Professional Guide to the risk of progressive multifocal leukoencephalopathy (PML) associated with Tysabri™ (<u>natalizumab</u>) and a related administration checklist for administering subcutaneous natalizumab outside a clinical setting. The guide discusses the risk factors for PML, its diagnosis, patient monitoring, and important considerations
- -- Novartis Fabhalta (<u>iptacopan</u>) Vaccination Confirmation Form to verify that iptacopan can only be dispensed once Novartis receives written confirmation that each patient has received vaccination against N. meningitidis and S. pneumoniae infections &/or receipt of prophylactic antibiotic treatment

Food and Drug Administration (FDA) USA

- FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flushes due to menopause - link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

- Information about Nitrosamine Impurities in Medications link
- FDA is alerting patients and health care professionals about the voluntary withdrawal of Oxbryta from the market due to safety concerns link

Health Canada

- Health Product InfoWatch, September 2024: Mounjaro PI updated with the risk of malnutrition

Specialist Pharmacy Services NHS UK

- Managing risks associated with oxytocin infusions during labour - link

TGA

- Substitution allowed to address shortage of Ryzodeg 70/30 FlexTouch insulin September 2024
- Update on supply of Mouniaro (tirzepatide) injections link
- Upcoming changes to supply of some insulin products link

PAPERS OF INTEREST

American Journal of Psychiatry

- Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women with Schizophrenia or Schizoaffective Disorder - link

Annals of Internal Medicine

- Ethics and Academic Discourse, Scientific Integrity, Uncertainty, and Disinformation in Medicine: An American College of Physicians Position Paper link
- Artificial Intelligence-Supported Development of Health Guideline Questions link

Arthritis & Rheumatology

- Efficacy Versus Effectiveness: The HORIZON-Pivotal Fracture Trial and Its Emulation in Claims Data link
- Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled Phase III INVIGORATE-2 Study link
- Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo-Controlled, Phase III INVIGORATE-1 Study $\underline{\text{link}}$
- Weight loss after initiating anti-obesity medications and gout among overweight and obesity individuals: a population-based cohort study $\underline{\text{link}}$
- Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis Link

British Journal of Clinical Pharmacology

- Efficiency of computerized clinical decision support systems involving anticoagulants: A flashmob study in Dutch hospital pharmacies link
- Flucloxacillin instantly decreases serum levels of valproic acid: A case report link
- Errors associated with co-names of medicines: The nomenclature of combination medicinal products link
- Efficacy and safety of antidepressants for pain in older adults: A systematic review and meta-analysis link
- The effect of down-titration and discontinuation of heart failure pharmacotherapy in older people: A systematic review and meta-analysis link
- Apixaban anti-Xa levels in clinical practice: A case report link
- MCF classifier: Estimating, standardizing, and stratifying medicine carbon footprints, at scale link
- Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis link
- Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist <u>link</u>
- Calcium channel blocker overdose: Not all the same toxicity link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

- Adoption of clinical pharmacist roles in primary care: Longitudinal evidence from English general practice <u>Link</u>
- Malaria in pregnancy: Modern approaches—Spotlight commentary link

British Journal of Psychiatry

- Clozapine, relapse, and adverse events: a 10-year electronic cohort study in Canada link
- Electroconvulsive therapy response and remission in moderate to severe depressive illness: a decade of national Scottish data Link

British Medical Journal (BMJ)

- Effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine against mpox infection: emulation of a target trial link
- Protecting early career physicians from commercial influence link
- Measures of how well a vaccine works link
- Stevens-Johnson syndrome/toxic epidermal necrolysis: initial assessment link
- Management of atrial fibrillation in older adults link
- Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis link
- Optimising inhaled therapy for patients with asthma link

BMJ Open

- Cost comparison analysis of continuous versus intermittent antimicrobial therapy infusions in inpatient and outpatient care: real-world data from Finland $\underline{\text{link}}$
- Prescription charge policy acceptance among UK adults with and without long-term health conditions: a mixed-method survey link

BMJ Quality & Safety

- Editorial: Measuring gist-based perceptions of medication benefit-to-harm ratios - link

Circulation

- 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines - Link

- Kidney Disease as a Cardiovascular Disease Priority - link

Cochrane

- Erythropoiesis-stimulating agents for preventing acute kidney injury link
- Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases link

Diabetes Care

- The Large Language Model GPT-4 Compared to Endocrinologist Responses on Initial Choice of Antidiabetic Medication under Conditions of Clinical Uncertainty <u>link</u>
- Glycemic and Psychosocial Outcomes of Advanced Hybrid Closed Loop Therapy in Youth With High HbA1c: A Randomized Clinical Trial link
- Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program <u>link</u>
- Initiation of Intermittently Scanned Continuous Glucose Monitoring Is Associated With Reduced Hospitalization for Acute Diabetes Events and Cardiovascular Complications in Adults With Type 1 Diabetes link

Drug and Therapeutics Bulletin

- Editorial: (Un)common sense in oncology link
- Recent updates from the BNF (BNF 88) link
- DTB select: Intravenous vitamin C for COVID-19-no benefit link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au
An initiative of NSW clinical pharmacologists & pharmacists

- Managing hypertension in older people: current concepts - link

European Heart Journal

- Clinical trials in-a-dish for cardiovascular medicine - link

European Journal of Hospital Pharmacy

- Pharmacoeconomic and clinical impact of pharmaceutical service in the intensive care unit: a systematic review - link

Heart

- Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study <u>link</u>
- Advancing the access to cardiovascular diagnosis and treatment among women with cardiovascular disease: a joint British Cardiovascular Societies' consensus document link

Internal Medicine Journal

- Progestogen hypersensitivity: successful use of progesterone desensitisation and omalizumab to facilitate in vitro fertilisation - \underline{link}

International Journal of Clinical Pharmacy

- A retrospective cohort study of coagulation function in patients with liver cirrhosis receiving cefoperazone/sulbactam with and without vitamin K1 supplementation <a href="https://link.pubm.nih.gov/link.gov
- Assessing the cost-effectiveness of replacing antimetabolites with mTOR inhibitors in heart transplant immunosuppression in China: a network meta-analysis-based economic evaluation link

International Journal for Quality in Health Care

- Optimizing Warfarin and Dual Oral Anticoagulation Practices in an Academic Clinic During a Merger Amid the COVID-19 Pandemic in a Marginalized Population <a href="https://link.google.com
- Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill link

JAMA

- JAMA Clinical Guidelines Synopsis: Evaluation of Suspected Antibiotic Allergies link
- Tenecteplase vs Alteplase for Patients with Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial <u>link</u>
- Why the Rise of This Drug-Resistant Fungus Is Raising International Concern link
- Chemistry Matters—From a Putative Peptide to Effective Treatments for Diabetes and Obesity: 2024 Lasker-DeBakey Clinical Medical Research Award link
- The Science of Biosimilars—Updating Interchangeability link
- RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older link

JAMA Dermatology

- Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials - <u>link</u>

JAMA Internal Medicine

- Reaction Risk to Direct Penicillin Challenges. A Systematic Review and Meta-Analysis link
- GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease <u>Link</u>
- Deprescribing of Antihypertensive Medications and Cognitive Function in Nursing Home Residents link
- Direct-to-Consumer Educational Brochures to Promote Gabapentinoid Deprescribing in Older Adults
- Patient-Directed Education to Promote Deprescribing: A Nonrandomized Clinical Trial link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

JAMA Network Open

- Community-Acquired Pneumonia A Review - link

JAMA Neurology

- Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine. A Phase 4, Randomized, Placebo-Controlled Trial <u>link</u>
- Comorbidity and Disease Activity in Multiple Sclerosis link
- Antiseizure Medication Use and Outcomes After Suspected or Confirmed Acute Symptomatic Seizures link
- Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation
- <u>link</u>

JAMA Psychiatry

- Clinical Outcomes of Continuation and Maintenance Electroconvulsive Therapy link
- Patient Self-Guided Interventions to Reduce Sedative Use and Improve Sleep: The YAWNS NB Randomized Clinical Trial <u>link</u>

Journal of the American College of Cardiology

- Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison from AUGUSTUS link
- Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared with Placebo for Initial Treatment of Hypertension <a href="https://link.gov/link

Journal of the American Medical Informatics Association

- Longitudinal study of the manifestations and mechanisms of technology-related prescribing errors in pediatrics - <u>link</u>

Journal of Clinical Oncology

- Naldemedine for Opioid-Induced Constipation in Patients with Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial link
- Racial Differences in Breast Cancer Survival Between Black and White Women According to Tumor Subtype: A Systematic Review and Meta-Analysis link
- Navigating Hormone Therapy in Postmenopausal Women: Balancing Symptom Relief with Cancer Risk link

Lancet

- Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 link
- Lipoprotein(a) and cardiovascular disease link
- Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial link

Lancet Diabetes & Endocrinology

- Osteopenia: a key target for fracture prevention - link

Lancet Gastroenterology and Hepatology

- Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis link
- Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis <u>link</u>
- Disorders of gastric motility link

Lancet HIV

- Role of HIV self-testing in strengthening HIV prevention services - link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au An initiative of NSW clinical pharmacologists & pharmacists

Lancet Infectious Diseases

- Optimising vaccine immunogenicity in ageing populations: key strategies link
- The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access link

Lancet Neurology

- Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 <u>link</u>
- Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, double-blind, head-to-head, crossover, non-inferiority, phase 3 trial <u>link</u>
- Safety and efficacy of memantine and trazodone versus placebo for motor neuron disease (MND SMART): stage two interim analysis from the first cycle of a phase 3, multiarm, multistage, randomised, adaptive platform trial link

Lancet Psychiatry

- Optimising psychiatric care through pain management - link

Molecular Diversity Preservation International (MDPI) - Pharmacy Journal

- Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales link
- Improving the Monitoring and Management of Clozapine-Induced Gastrointestinal Hypomotility (CIGH) in Community Mental Health Services: A Quality Improvement Approach <u>link</u>

Medical Journal of Australia

- Summary of the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome: an Australian perspective link
- Updating the diagnosis and management of iron deficiency in the era of routine ferritin testing of blood donors by Australian Red Cross Lifeblood link
- 6-Methylnicotine: a new nicotine alternative identified in e-cigarette liquids sold in Australia link

New England Journal of Medicine

- Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment link
- Liraglutide for Children 6 to <12 Years of Age with Obesity A Randomized Trial link
- Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer link
- Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma link
- Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer link
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma link
- Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer link
- Pembrolizumab in HER2-Positive Gastric Cancer link
- Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer link
- Ponsegromab for the Treatment of Cancer Cachexia link
- Preoperative Chemoradiotherapy for Resectable Gastric Cancer link
- Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer link
- Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma link
- Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors link
- Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease link
- Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia link
- Primary Central Nervous System Vasculitis link

Pediatrics

- Special Requirements of Electronic Health Record Systems in Pediatrics: Clinical Report link
- Use of Antibiotics in Animal Agriculture: Implications for Pediatrics: Technical Report link
- Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children link
- Posterior Reversible Encephalopathy Syndrome Due to Vitamin D Toxicity link

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au
An initiative of NSW clinical pharmacologists & pharmacists

Pharmaceutical Journal

- Mpox: how is the UK preparing for the latest variant? - link

Pharmacotherapy

- Delirium event and associated treatment modifications among older adults with Alzheimer's disease: An interrupted time-series analysis of Medicare data - <u>link</u>

Research in Social and Administrative Pharmacy

- Relationships between medications used in a mental health hospital and types of medication errors: A cross-sectional study over an 8-year period - link

Thorax

- Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis link
- Intensive care unit interventions to promote sleep and circadian biology in reducing incident delirium: a scoping review <u>link</u>

CONSULTATIONS

Agency for Clinical Innovation, NSW (ACI)

- Consultation: Stroke Intravenous Thrombolysis - closes 4 October 2024 - link

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Draft Medication Management at Transitions of Care Stewardship Framework - Closing 27 October 2024 - <u>link</u>

TGA

- Consultation on temporary labelling exemptions for paracetamol Closes 30 September 2024 link
- Consultation: Draft Guidance Regulatory changes for medical devices containing medicinal substances or materials of animal, microbial or recombinant origin Closes on 9 October 2024 https://link.pubm.nicrobial.org/
- Consultation: Clarifying and strengthening the regulation of Artificial Intelligence (AI) Closes on 13 October 2024 link
- Consultation: Proposed amendments to the Poisons Standard ACMS and Joint ACMS-ACCS meetings, November 2024 Closes on 22 October 2024 <u>link</u>
- Public consultation on interim decisions to amend the Poisons Standard ACMS, ACCS & Joint ACMS-ACCS JUNE, 2024 Closes on 18 October 2024 link

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- Episode 172: Utility of common investigations for suspected inflammatory arthritis in adults

MJA Podcasts

- Episode 24: Interventional techniques in stroke treatment

Purple Pen Podcast

- PPP 165: Fever with A/Prof Rebekah Moles
- <u>PPP 166</u>: Special Episode World Pharmacist Day 2024 Pharmacist Wellbeing with Dr Karlee Johnston

UPCOMING EVENTS

AHHA

- 'Cyber safety is patient safety': Lessons from the U.S. on securing the health system from cyber attacks October 3, 2024 08:00-09:00 AEST $\underline{\text{link}}$ $\underline{\text{register}}$
- The John Deeble Lecture and Panel Discussion, Beyond boundaries: leadership for health National Museum of Australia, Canberra, ACT October 15, 2024 09:00-16:00 AEST register

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- First national Chronic Obstructive Pulmonary Disease Clinical Care Standard Launch, with expert panel discussion Thursday 17 October 12:00–13:00 AEDT register
- NMS 2024: Ageing well: safe medicines, better lives Tuesday, 19 November 2024 10.00- 15.00 Register

Institute for Healthcare Improvement-BMJ Group

- The International Forum on Quality and Safety in Healthcare, Brisbane, 6-8 November 2024 – registration

Society of Hospital Pharmacists (SHPA)

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 - early-bird <u>registration</u> closes 11:59pm AEST Thursday 3 October 2024

TGA

- Product standards for therapeutic vaping goods webinar - an overview of changes to the product standards commencing early 2025 - Thursday 3 October 2024 12:00-13:00 AEST - register

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988 Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists